Single or combined immune checkpoint inhibitors compared to first‐line chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: Primary To determine the efficacy and safety of first‐line immune checkpoint inhibitors, or immuno‐oncology therapy (IO), as monotherapy or in combination for patients with advanced non‐small cell lung cancer (NSCLC). Secondary To maintain the currency of evidence by taking a living systematic review approach.